Juan Domingo Gispert1, Marc Suárez-Calvet2, Gemma C Monté3, Alan Tucholka4, Carles Falcon5, Santiago Rojas6, Lorena Rami3, Raquel Sánchez-Valle3, Albert Lladó3, Gernot Kleinberger7, Christian Haass8, José Luis Molinuevo9. 1. Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain; Pompeu Fabra University, Barcelona, Spain. 2. BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. 3. Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 4. Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain. 5. Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain. 6. Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Unit of human Anatomy and Embryology, Department of Morphological Sciences, Faculty of Medicine, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain. 7. BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 8. BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 9. Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: jlmolinuevo@fpmaragall.org.
Abstract
INTRODUCTION: TREM2 is involved in the regulation of inflammatory response and phagocytosis. A soluble fragment (sTREM2) is often found abnormally increased in cerebrospinal fluid (CSF) in Alzheimer's disease (AD). METHODS: One hundred fourteen participants (45 control, 19 preclinical, 27 mild cognitive impairment [MCI], and 23 AD) underwent CSF sTREM2 determination and magnetic resonance imaging (MRI). We studied the association between CSF sTREM2, gray matter volume, and water motion diffusivity and anisotropy across groups. RESULTS: In MCI patients, a positive correlation between CSF sTREM2 and gray matter volume was found in the bilateral inferior and middle temporal cortices, precuneus, the supramarginal, and angular gyri, after controlling by age, sex, and p-tau. A negative correlation with mean diffusivity was detected in overlapping regions, among others. DISCUSSION: In early AD, augmented CSF sTREM2 levels correspond with cerebral MRI features typical of brain swelling, supporting a role for TREM2 in the regulation of the neuroinflammatory response to early neurodegeneration.
INTRODUCTION:TREM2 is involved in the regulation of inflammatory response and phagocytosis. A soluble fragment (sTREM2) is often found abnormally increased in cerebrospinal fluid (CSF) in Alzheimer's disease (AD). METHODS: One hundred fourteen participants (45 control, 19 preclinical, 27 mild cognitive impairment [MCI], and 23 AD) underwent CSF sTREM2 determination and magnetic resonance imaging (MRI). We studied the association between CSF sTREM2, gray matter volume, and water motion diffusivity and anisotropy across groups. RESULTS: In MCI patients, a positive correlation between CSF sTREM2 and gray matter volume was found in the bilateral inferior and middle temporal cortices, precuneus, the supramarginal, and angular gyri, after controlling by age, sex, and p-tau. A negative correlation with mean diffusivity was detected in overlapping regions, among others. DISCUSSION: In early AD, augmented CSF sTREM2 levels correspond with cerebral MRI features typical of brain swelling, supporting a role for TREM2 in the regulation of the neuroinflammatory response to early neurodegeneration.
Authors: Michael Ewers; Nicolai Franzmeier; Marc Suárez-Calvet; Estrella Morenas-Rodriguez; Miguel Angel Araque Caballero; Gernot Kleinberger; Laura Piccio; Carlos Cruchaga; Yuetiva Deming; Martin Dichgans; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; Christian Haass Journal: Sci Transl Med Date: 2019-08-28 Impact factor: 17.956
Authors: F Sampedro; S Martínez-Horta; J Perez-Perez; A Horta-Barba; J Martin-Lahoz; A Alonso-Solís; I Corripio; B Gomez-Anson; J Kulisevsky Journal: AJNR Am J Neuroradiol Date: 2019-09 Impact factor: 3.825
Authors: L M Bekris; M Khrestian; E Dyne; Y Shao; J A Pillai; S M Rao; S M Bemiller; B Lamb; H H Fernandez; J B Leverenz Journal: J Neuroimmunol Date: 2018-03-20 Impact factor: 3.478
Authors: Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer Journal: Dement Geriatr Cogn Disord Date: 2020-04-28 Impact factor: 2.959
Authors: Michael L Alosco; Yorghos Tripodis; Nathan G Fritts; Amanda Heslegrave; Christine M Baugh; Shannon Conneely; Megan Mariani; Brett M Martin; Samuel Frank; Jesse Mez; Thor D Stein; Robert C Cantu; Ann C McKee; Leslie M Shaw; John Q Trojanowski; Kaj Blennow; Henrik Zetterberg; Robert A Stern Journal: Alzheimers Dement Date: 2018-07-23 Impact factor: 21.566
Authors: Grace E Weber; Katherine A Koenig; Maria Khrestian; Yvonne Shao; Elizabeth D Tuason; Marie Gramm; Dennis Lal; James B Leverenz; Lynn M Bekris Journal: J Immunol Date: 2020-01-20 Impact factor: 5.422